An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) That are Refractory to Treatment

Trial Profile

An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) That are Refractory to Treatment

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs Amikacin (Primary)
  • Indications Mycobacterium avium complex infections; Respiratory tract infections
  • Focus Adverse reactions
  • Sponsors Insmed
  • Most Recent Events

    • 03 Jan 2018 According to an Insmed media release, 163 patients have been enrolled as of December 2017.
    • 03 Jan 2018 Interim results (n=124) presented in an Insmed media release.
    • 30 Aug 2017 This trial has been completed in Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top